These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 32685602

  • 1. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A.
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [Abstract] [Full Text] [Related]

  • 2. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A.
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [Abstract] [Full Text] [Related]

  • 3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA, Barner JC.
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [Abstract] [Full Text] [Related]

  • 4. Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post-2016 CDC Guideline.
    Kang HA, Wang B, Barner JC, Ataga KI, Mignacca RC, Chang A, Zhang Y.
    JAMA Intern Med; 2024 May 01; 184(5):510-518. PubMed ID: 38466269
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
    Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A.
    J Med Econ; 2020 Nov 01; 23(11):1345-1355. PubMed ID: 32815766
    [Abstract] [Full Text] [Related]

  • 7. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
    Kanter J, Bhor M, Li X, Li FY, Paulose J.
    J Health Econ Outcomes Res; 2019 Nov 01; 6(3):174-184. PubMed ID: 32685589
    [Abstract] [Full Text] [Related]

  • 8. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
    Shah N, Bhor M, Xie L, Paulose J, Yuce H.
    J Health Econ Outcomes Res; 2020 Nov 01; 7(1):52-60. PubMed ID: 32685598
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Vaso-occlusive Crises in United States Sickle Cell Disease Patients: A Retrospective Claims-based Study.
    Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H.
    J Health Econ Outcomes Res; 2019 Nov 01; 6(3):106-117. PubMed ID: 32685584
    [Abstract] [Full Text] [Related]

  • 10. Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies.
    Coyne KS, Currie BM, Callaghan M, Wyrwich KW, Pease S, Baker CL, Arkin S, Pittman DD.
    Eur J Haematol; 2022 Sep 01; 109(3):226-237. PubMed ID: 35569114
    [Abstract] [Full Text] [Related]

  • 11. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C, Evans KA, Yang Y, Lillehaugen T, Manjelievskaia J, Mujumdar U, Li N, Andemariam B.
    Adv Ther; 2023 Aug 01; 40(8):3543-3558. PubMed ID: 37332020
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
    Marfo K, Dei-Adomakoh Y, Segbefia C, Dwomoh D, Edgal A, Ampah N, Ramachandrachar BC, Subramanyam K, Natarajan A, Egbujo O, Ataga KI.
    BMC Health Serv Res; 2023 Sep 21; 23(1):1018. PubMed ID: 37735428
    [Abstract] [Full Text] [Related]

  • 13. Characterization of opioid use in sickle cell disease.
    Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS.
    Pharmacoepidemiol Drug Saf; 2018 May 21; 27(5):479-486. PubMed ID: 28815799
    [Abstract] [Full Text] [Related]

  • 14. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
    Rollé A, Vidal E, Laguette P, Garnier Y, Delta D, Martino F, Portecop P, Etienne-Julan M, Piednoir P, De Jong A, Romana M, Bernit E.
    Medicina (Kaunas); 2023 Dec 18; 59(12):. PubMed ID: 38138299
    [Abstract] [Full Text] [Related]

  • 15. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Kang HA, Barner JC, Lawson KA, Rascati K, Mignacca RC.
    Am J Hematol; 2023 Jan 18; 98(1):90-101. PubMed ID: 36251408
    [Abstract] [Full Text] [Related]

  • 16. Opioid Use in Patients With Sickle Cell Disease During a Vaso-Occlusive Crisis: A Systematic Review.
    Arzoun H, Srinivasan M, Sahib I, Fondeur J, Escudero Mendez L, Hamouda RK, Mohammed L.
    Cureus; 2022 Jan 18; 14(1):e21473. PubMed ID: 35106256
    [Abstract] [Full Text] [Related]

  • 17. IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
    Assad O, Zamora R, Brown K, Melnitsky L, Moses J, Sherman V.
    Am J Emerg Med; 2023 Feb 18; 64():86-89. PubMed ID: 36481614
    [Abstract] [Full Text] [Related]

  • 18. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N, Bhor M, Xie L, Paulose J, Yuce H.
    PLoS One; 2019 Feb 18; 14(7):e0214355. PubMed ID: 31276525
    [Abstract] [Full Text] [Related]

  • 19. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
    Zaidi AU, Glaros AK, Lee S, Wang T, Bhojwani R, Morris E, Donohue B, Paulose J, Iorga ŞR, Nellesen D.
    Orphanet J Rare Dis; 2021 Nov 02; 16(1):460. PubMed ID: 34727959
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.